Emergent BioSolutions Founder Fuad El-Hibri Dies Weeks After Retirement

Published on :

Emergent BioSolutions Founder Fuad El-Hibri Dies Weeks After Retirement
Published: May 02, 2022 By Alex Keown
Fuad El-Hibri/Courtesy of The Washington Post/Getty Images
Weeks after stepping down from his role as executive chairman of Emergent BioSolutions, company founder and former chief executive officer Fuad El-Hibri has died.
In a brief statement issued by Maryland-based Emergent, El-Hibri died at home last week died at his home, surrounded by family. No cause of death was provided by the company, however, The New York Times reported that the cause of death was related to pancreatic cancer. El-Hibri was 64.
El-Hibri stepped down from his role as executive chairman on April 1. He initially announced his decision at the beginning of the year.
“Creating and leading Emergent has been the honor of my life, and it would not have been possible without the help of our incredible team,” El-Hibri said in a statement when he announced his retirement. “I want to thank everyone at Emergent, past and present, for helping advance our inspiring mission over the past two decades. I could never have imagined the number of lives we would impact, and I will forever be proud of our accomplishments. Emergent is on track…

Emergent’s Recent Rebrand – A Symbol of Defense and Determination

Published on :

Emergent BioSolutions is no doubt one of the most widely-known biotechnology companies in the BioHealth Capital Region, with numerous locations in Gaithersburg, Baltimore, and beyond. If you’re a follower of Emergent, you’ve probably noticed a change in their corporate look and feel over the past few months.

Emergent BioSolutions: The path to re-emergence

Published on :

Emergent BioSolutions was arguably one batch away from being a pandemic hero. 
Just months after COVID-19 gripped the world, the Maryland-based life sciences company had locked in deals to manufacture two of the five leading Operation Warp Speed vaccine candidates. 
Shortly after Emergent had inked what eventually became a five-year deal worth at least $480 million with Johnson & Johnson to produce bulk drug substance for Janssen’s vaccine candidate, the U.S. government issued a $628 million task order to reserve capacity for a second OWS innovator — AstraZeneca. This resulted in Emergent signing an additional $261 million deal to make drug substances for the AstraZeneca-Oxford vaccine candidate. 

Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

Published on :

Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Emergent BioSolutions Expanding Quality Assurance Team

Emergent logo with "Now Hiring" sign, photo of two Emergent employees talking in an office
Published on :

Quality assurance is a key function in the biopharma industry that provides a hands-on role in day-to-day operations. It’s a role that allows team members to maintain their fingers on the pulse of the beating heart of a drug manufacturing company. And it’s a role that’s available at one of the biggest drug manufacturing companies in the BioHealth Capital Region.

Are You a Veteran on the Job Market? A Biotech Career Could Be the Perfect Fit

Screenshot of V2I Zoom presentation
Published on :

The solution to finding a career with similar purpose and meaning could await you in the life sciences industries, where we don’t make widgets. We make products that save, protect, enhance, and empower people every day, and we need veterans in our workforce to be successful.

Seeking Top Biotech Talent? Veterans Have Just What You Need

Published on :

Every month, thousands of military veterans around the world begin their transition out of the military with anywhere between 2 and 20 years of experience in some of the most fast-paced, operationally focused, and regulated environments imaginable. These transitioning service-members and their families all bring an army of benefits to bear for innovative organizations willing to give them a chance. 

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

Published on :

Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease, including adults 55 and older and those 18 and older who are immunocompromised.

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

Published on :

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.

The Storied 25 Year History Behind the Baltimore Biotech Manufacturing Facility Producing COVID-19 Vaccines

Published on :

Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines.  However, the history of this facility goes back more than two decades.